Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy

CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report

(2023) Dong-Wan Kim et al.   Journal of Thoracic Oncology

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors

(2023) Anthony W Tolcher et al.   Journal for ImmunoTherapy of Cancer

Hallmarks of Cancer: New Dimensions

(2022) Douglas Hanahan   Cancer Discovery

Adenosine metabolized from extracellular ATP promotes type 2 immunity through triggering A2BAR signaling in intestinal epithelial cells

(2022) Darine W. El-Naccache et al.   Cell Reports

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

(2022) Emerson A. Lim et al.   CLINICAL CANCER RESEARCH

A2AR limits IL-15-induced generation of CD39+ NK cells with high cytotoxicity

(2022) Guijie Kang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma

(2021) Pedro Rocha et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).

(2021) Gulam Abbas Manji et al.   JOURNAL OF CLINICAL ONCOLOGY

OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy

(2021) B. Besse et al.   Journal of Thoracic Oncology

Editorial: Purinergic Signaling and Inflammation

(2021) Xiaoyi Yuan et al.   Frontiers in Immunology

Release of adenosine-induced immunosuppression: Comprehensive characterization of dual A2A/A2B receptor antagonist

(2021) Katarzyna Dziedzic et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).

(2021) Sumit Kumar Subudhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).

(2021) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

(2021) Lauren Giuffrida et al.   Nature Communications

The elegant complexity of mammalian ecto-5′-nucleotidase (CD73)

(2021) Karel P. Alcedo et al.   TRENDS IN CELL BIOLOGY

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

(2021) Darci Phillips et al.   Nature Communications

Adenosine signalling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response

(2020) Ben Sidders et al.   CLINICAL CANCER RESEARCH

CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint

(2020) Miao Yu et al.   Nature Communications

CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection

(2020) Erik Wennerberg et al.   Cancer Immunology Research

The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8+ T-cell Responses and Promotes Tumor Growth

(2020) Siqi Chen et al.   Cancer Immunology Research

The adenosine pathway in immuno-oncology

(2020) Bertrand Allard et al.   Nature Reviews Clinical Oncology

Glioma patient profiling reveals the dominant immune suppressive adenosine axis is refractory to immune function restoration

(2020) Martina Ott et al.   JCI Insight

348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

(2020) D. Eiger et al.   ANNALS OF ONCOLOGY

Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches

(2020) Elizabeth A. Thompson et al.   Annual Review of Medicine

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

(2020) Roberta Turiello et al.   Journal for ImmunoTherapy of Cancer

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy

(2019) Siqi Chen et al.   Nature Communications

Purine Release, Metabolism, and Signaling in the Inflammatory Response

(2019) Joel Linden et al.   Annual Review of Immunology

CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling

(2019) Angela Yan et al.   JOURNAL OF NEUROSCIENCE

CD73: an emerging checkpoint for cancer immunotherapy

(2019) Siqi Chen et al.   Immunotherapy

A2B Adenosine Receptor and Cancer

(2019) Zhan-Guo Gao et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity

(2019) Juliana Hofstätter Azambuja et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

(2019) Lawrence Fong et al.   Cancer Discovery

Adenosine Metabolism: Emerging Concepts for Cancer Therapy

(2019) Detlev Boison et al.   CANCER CELL

CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment

(2019) Shi Yong Neo et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

(2019) Sangeeta Goswami et al.   NATURE MEDICINE

Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models

(2018) Robert D. Leone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Pharmacology of Adenosine Receptors: The State of the Art

(2018) Pier Andrea Borea et al.   PHYSIOLOGICAL REVIEWS

Immunomodulatory role of Keratin 76 in oral and gastric cancer

(2018) Inês Sequeira et al.   Nature Communications

A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models

(2018) Stephen B. Willingham et al.   Cancer Immunology Research

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

(2017) Bertrand Allard et al.   IMMUNOLOGICAL REVIEWS

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

(2017) Silvana Morello et al.   Journal of Translational Medicine

Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer

(2017) Yusuke Inoue et al.   Oncotarget

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment

(2017) Melanie Mediavilla-Varela et al.   NEOPLASIA

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

(2016) Arabella Young et al.   CANCER CELL

Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis

(2016) D. Mittal et al.   CANCER RESEARCH

A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer

(2016) Stephen M Hatfield et al.   CURRENT OPINION IN PHARMACOLOGY

Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?

(2016) Pier Andrea Borea et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

CD73 is associated with poor prognosis in HNSCC

(2016) Zhen-Hu Ren et al.   Oncotarget

Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression

(2016) Claudia Sorrentino et al.   Oncotarget

CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

(2015) Martin Turcotte et al.   CANCER RESEARCH

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer

(2015) B. G. Leclerc et al.   CLINICAL CANCER RESEARCH

CD73: A potential biomarker for anti-PD-1 therapy

(2015) Paul A Beavis et al.   OncoImmunology

Blockade of A2b Adenosine Receptor Reduces Tumor Growth and Immune Suppression Mediated by Myeloid-Derived Suppressor Cells in a Mouse Model of Melanoma

(2015) Raffaella Iannone et al.   NEOPLASIA

Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment

(2014) C. Cekic et al.   CANCER RESEARCH

Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment

(2014) C. Cekic et al.   CANCER RESEARCH

Role of TGF-β Signaling in Generation of CD39+CD73+Myeloid Cells in Tumors

(2014) Sergey V. Ryzhov et al.   JOURNAL OF IMMUNOLOGY

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

(2013) B. Allard et al.   CLINICAL CANCER RESEARCH

Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis

(2013) Lei Qin et al.   Immunotherapy

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis

(2013) C. J. Desmet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD73 as a novel prognostic biomarker for human colorectal cancer

(2012) Nan Liu et al.   JOURNAL OF SURGICAL ONCOLOGY

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

(2011) Adam T. Waickman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Adenosine promotes alternative macrophage activation via A2A and A2B receptors

(2011) Balázs Csóka et al.   FASEB JOURNAL

Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells

(2011) S. Ryzhov et al.   JOURNAL OF IMMUNOLOGY

A2B Adenosine Receptor Blockade Enhances Macrophage-Mediated Bacterial Phagocytosis and Improves Polymicrobial Sepsis Survival in Mice

(2011) B. G. Belikoff et al.   JOURNAL OF IMMUNOLOGY

The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells

(2009) J. M. Wilson et al.   JOURNAL OF IMMUNOLOGY

A2B adenosine receptors in immunity and inflammation

(2009) György Haskó et al.   TRENDS IN IMMUNOLOGY

Adenosine receptors in regulation of dendritic cell differentiation and function

(2008) S. V. Novitskiy et al.   BLOOD

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER